News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Coronado Biosciences Initiates Phase 2 Clinical Trial of TSO for the Treatment of Crohn's Disease


8/14/2012 9:34:46 AM

BURLINGTON, Mass., Aug. 14, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc., (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, announced today the initiation of TRUST- I (TRichUris Suis ova Trial), a Phase 2 clinical trial of TSO (Trichuris suis ova or CNDO-201) in patients with Crohn's disease. TSO, the microscopic eggs of the porcine whipworm, is a novel, orally administered, natural immunomodulator that regulates T-Cells and inflammatory cytokines.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES